| abstract |
The invention relates to a compound which is (S)-4-((S)-3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8- naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid(1:1) citrate salt, pharmaceutical compositions including such compound, and to the use of such compound in therapy, including in the treatment of a disease or condition for which an α v β 6 integrin antagonist is indicated, and in particular idiopathic pulmonary fibrosis. |